HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies

A significant shift in the ownership structure of pharmaceutical player Corona Remedies Limited occurred on June 17, 2026, as major institutional investors stepped in to acquire a substantial stake. This massive block deal marks a key movement in the healthcare sector, involving some of the world’s most prominent asset management firms.

Massive Divestment by Sepia Investments and Anchor Partners

The block deal was headlined by Sepia Investments, which offloaded 43,28,943 shares of Corona Remedies. Executed at a price of ₹1,730 per share, the transaction by Sepia alone amounted to approximately ₹748.9 crore. Adding to the sell-side momentum, Anchor Partners also divested its holdings, selling 1,61,861 shares at the same price point, worth roughly ₹28 crore.

In total, these two sellers successfully exited or reduced their positions by offloading shares worth approximately ₹776.9 crore in the pharmaceutical company, signaling a major liquidity event in the stock.

HDFC Mutual Fund Dominates the Buy Side

While the sell-side was concentrated among two entities, the buy-side saw intense participation from twelve different institutional investors. HDFC Mutual Fund emerged as the most aggressive buyer, single-handedly absorbing more than half of the total deal value. HDFC MF acquired 24,50,000 shares, an investment totaling roughly ₹423.9 crore.

Other heavyweight domestic and international players also secured significant positions:

• Aditya Birla Sun Life Mutual Fund: Purchased 4,90,000 shares worth ₹84.8 crore.
• Aberdeen Asian Smaller Companies Investment Trust Plc: Bought 4,50,868 shares valued at ₹78 crore.
• Invesco Mutual Fund: Acquired 2,89,017 shares for approximately ₹50 crore.
• Kotak Mahindra Mutual Fund: Picked up 1,61,861 shares worth ₹28 crore, a volume that exactly matched the quantity sold by Anchor Partners.

Global Institutional Interest in Corona Remedies

The deal also highlights growing interest from global sovereign wealth funds and specialized emerging market funds. The Abu Dhabi Investment Authority (ADIA) participated in the deal, purchasing 39,130 shares worth approximately ₹6.8 crore.

De plus, le groupe WhiteOak a fait preuve d'une conviction significative, l'Ashoka WhiteOak Emerging Markets Equity Fund ayant acheté 148 686 actions (25,7 crores ₹) et WhiteOak Capital Mutual Fund ayant acquis 145 000 actions (25,1 crores ₹). D'autres participants incluaient Aberdeen Standard Sicav I, India Acorn ICAV et Factory Mutual Insurance Company, soulignant la confiance institutionnelle généralisée envers la société au niveau de prix de 1 730 ₹.

Points clés

• Transfert de participation majeur : Sepia Investments et Anchor Partners ont cédé un total combiné d'environ 776,9 crores ₹ dans Corona Remedies via une transaction de bloc.
• HDFC MF en tant qu'acheteur principal : HDFC Mutual Fund a été le principal acquéreur, investissant 423,9 crores ₹ pour 24,5 lakhs d'actions, ce qui représente plus de 50 % de la valeur de la transaction.
• Forte appétence institutionnelle : La transaction a vu la participation d'un groupe diversifié de 12 investisseurs, incluant des géants mondiaux comme ADIA et Aberdeen, aux côtés de grands fonds communs de placement indiens.